MAGEA10 and sarcoma: Given data that MAGE−A10 expression frequently overlaps with MAGE-A4 expression (Adaptimmune, data on file), this trial was closed and several trials with adoptive cellular therapies targeting MAGE-A4, including a registrational study in sarcoma, are now ongoing (NCT03132922, NCT04044768, and NCT04044859).